Decreased level of serum NT-proCNP associates with disease severity in COVID-19

Respiratory Research

Table 3 Baseline characteristics, cardiovascular risk profile, comorbidities and relevant medications of the mild and severe COVID-19 patients

Characteristics	Mild COVID-19 (n = 20)	Severe COVID-19 (n = 12)	p value
Baseline characteristics
Age years (SD)	58.4 (15.7)	62.4 (13.9)	0.47
Female n (%)	12 (60)	4 (33)	0.27
BMI kg/m² (IQR)	26.2 (7)	27.4 (10.6)	0.46
Previous medical history
Hypertension n (%)	6 (30)	6 (50)	0.29
Diabetes mellitus n (%)	3 (15)	4 (33.3)	0.38
Chronic kidney disease n (%)	4 (11.4)	4 (12.5)	1.0
Coronary artery disease n (%)	2 (10)	0 (0)	0.52
Heart failure n (%)	1 (5)	1 (8.3)	1.0
Cancer n (%)	6 (30)	4 (33.3)	1.0
Smoker n (%)	11 (55)	3 (25)	0.15
Pulmonary pathology n (%)	4 (20)	5 (41)	0.24
Relevant cardiovascular medications
ACEI n (%)	0 (0)	2 (17)	0.13
ARB n (%)	6 (30)	2 (17)	0.68
CCB n (%)	2 (10)	5 (41.7)	0.07

Continuous variables were described using mean and standard deviation (SD) for symmetric, and median and interquartile range (IQR) for asymmetric distributions. p values are from Wilcoxon’s rank-sum test (continuous variables) or Fisher’s exact test (categorical variables). Pulmonary pathology is defined as COPD, prior pulmonary embolism or pulmonary fibrosis in the anamnesis
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, BMI body mass index, CCB Ca²⁺ channel blocker, COPD chronic obstructive pulmonary disease, COVID-19 coronavirus disease 2019, IQR interquartile range

ISSN: 1465-993X